Skip to main content
Equibles
BGMS logo

BGMS · Bio Green Med Solution, Inc.

Track BGMS — free

Use BGMS with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.83 -0.02 (-2.24%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Our history of losses, our negative cash flows from operations, our liquidity resources currently on hand, and our dependence on the ability to obtain additional financing to fund our operations after the current resources are exhausted, about which there can be no certainty, have resulted in our assessment that there is substantial doubt about our ability to continue as a going concern for a period of at least twelve months from the issuance date of this Quarterly Report on Form 10-Q.”
View the 10-Q filed Aug 14, 2026
Market Cap
$5.73M
Shares
6.62M

BGMS metrics

53 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.85
Market cap
$5.73M

Price action

19 metrics
Price change (1W)
-3.4%
Price change (30D)
-3.4%
Price change (3M)
-22.0%
Price change (6M)
-11.5%
Price change (YTD)
-42.6%
Price change (1Y)
-89.7%
Trailing year
Price change (5Y)
—
52-week high
$7.69
52-week low
$0.60
Change from 52-week high
-88.9%
Change from 52-week low
+41.7%
Annualized volatility
121.2%
Beta
1.2
RSI (14D)
41.3
Price vs SMA 50
-4.3%
Price vs SMA 200
-21.1%
Avg volume (3M)
2.25M
Relative volume
0.0
Average dollar volume
$3.09M

Company

3 metrics
Sector
Industrials
Industry
Building Products & Equipment
Shares outstanding
6.62M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
70.7×
reciprocal yield 1.4%
P / book
0.8
reciprocal yield 125.0%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-38.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
2025-04-29

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2024-08-14

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$3.63M
Net income (TTM)
−$2.20M
Trailing 12 months
Diluted EPS (TTM)
$-6.45
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$22,114.89

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$81,000
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+311.5%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-30.7%
Return on assets
-28.0%
Debt / equity
—
Current ratio
8.6
EBITDA (TTM)
−$15.97M
Free cash flow (TTM)
—
Quick ratio
7.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$3.79M
Total assets
$7.85M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$1.10M
Capital expenditures (TTM)
—
R&D (TTM)
$848,000
SG&A (TTM)
$5.39M
Stock compensation (TTM)
$662,000
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
7
13F filer change QoQ
-3
Institutional ownership
1.5%

Short interest

3 metrics
Short interest
0.9%
Latest settlement · 1.5 days to cover
Days to cover
1.5d
Short-squeeze score
37 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1130166 CUSIP 23254L876 13F (30d) 8 filings 8 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)